Table 2.
Predicted Neoantigens for SCLC (This Study) and LUAD (TCGA)
| Tumor Type | Mutations (n) | Neoantigens (n) | Neoantigens Per Mutation |
|---|---|---|---|
| SCLC (n = 85) | |||
| nsSNVs | 21,059 | 3299 | 0.16 |
| fs-indels | 1346 | 662 | 0.49 |
| fs-indel enrichment | 3.14 | ||
| LUAD (top 10 for TMB) | |||
| nsSNVs | 1013 | 118 | 0.12 |
| fs-indels | 219 | 132 | 0.60 |
| fs-indel enrichment | 5.17 | ||
| LUAD (bottom 10 for TMB) | |||
| nsSNVs | 38 | 3 | 0.08 |
| fs-indels | 20 | 47 | 2.35 |
| fs-indel enrichment | 29.8 |
LUAD, lung adenocarcinoma; TCGA, The Cancer Genome Atlas; nsSNVs, nonsynonymous single-nucleotide variants; fs-indels, frameshift insertions and deletions; TMB tumor mutation burden.